FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzersAugust 9, 2022
STOCKHOLM, SWEDEN, - August 9, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that the FDA (US Food and Drug Administration) held a meeting with the Medical Devices Advisory Committee on July 28th and 29th to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection.
Annual general meeting has been held in SciBase Holding AB (publ) 2022May 18, 20222022-05-18 14:15 Today, the annual general meeting of 2022 was held in SciBase Holding AB (publ) (the “Company” or “SciBase”). Below follows a summary of the resolutions passed at the annual general meeting. The annual general meeting resolved: to adopt the profit and loss statement and the balance sheet and the group profit and loss […]
US study shows that EIS and Nevisense significantly improves clinicians’ diagnostic accuracyMay 16, 2022
STOCKHOLM, SWEDEN, - May 16, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published in the US demonstrated that EIS and Nevisense can significantly improve clinical decisions in the dermatology day-to-day practice, especially for less experienced clinicians. The study titled - "Diagnostic Efficacy Of Electrical Impedance Spectroscopy Versus Dermoscopy For Pigmented Skin Lesions: A Pilot Study" and authored by Dr Jonathan Ungar, Associate Director and Assistant Professor, Dermatology Department, et al at Icahn School of Medicine at Mount Sinai, New York, was published online in "SKIN-The Journal of Cutaneous medicine".
- Load more news...